Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy,
and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a
functional, well-differentiated NET, with carcinoid symptoms.